From co hosting the Innovative Medicine Forum in Hong Kong in 2025 to embedding itself in the core agenda of BIOHK as a co organizer in 2026, the journey of going global has significantly accelerated.

 Cheng Zengjiang, founder/chairman of Tongfreehand, vice president of the China Food and Drug Safety Promotion Association, and executive chairman of the CPIC Global Conference on New Drugs, stated in his speech that Tongfreehand has always been committed to promoting Chinese new drugs to the world.

Cheng Zengjiang pointed out that Hong Kong is a super contact for connecting the mainland and the world. The landing of this forum in Hong Kong is to rely on Hong Kong's international advantages, connect mainland R&D resources with global market channels, and explore the industrial cooperation path of "Chinese R&D, Hong Kong empowerment, and global market".
 

In his speech, Yu Changhai, Chairman of the Hong Kong Biotechnology Association, turned his attention to the Greater Bay Area.  

Yu Changhai stated that Hong Kong's internationalization rules are highly complementary to the industrial depth of the Greater Bay Area, and platforms such as Nansha are becoming accelerators for innovative drugs to go global. He looks forward to continuing to play a linking role with Tongyi and promoting more Chinese original achievements from the Greater Bay Area to the world.
 

In the keynote speech segment, five guests approached from different dimensions and pieced together a roadmap for biopharmaceuticals going global.

Liu Jin, Vice Chairman of the Hong Kong China Financial Association and co-founder of Wesker Biotech, shared his insights on Hong Kong's five-year plan, international industry university research cooperation, and biopharmaceutical investment, providing a panoramic perspective from policy windows to capital paths.

Xie Jiasheng, Vice Chairman of Guangzhou Nansha Association for Science and Technology and Executive President of Guangdong Medical Valley, shared the latest practices of international cooperation in life and health and the construction of Guangdong Medical Valley platform under the five-year plan of Guangzhou and Nansha.

Ding Jiandong, Director of the National Key Laboratory of Polymer Molecular Engineering and Chief Scientist of the National Major Scientific Research Program, focuses on the clinical translation of biomedical polymer materials and the application of regenerative medicine, presenting the prospect of cutting-edge technology moving from the laboratory to the global market.

Song Bilian, founder and CEO of Hualong Technology, showcased the breakthrough application of Hualong's new intelligent decision-making system in financial and health research and service innovation analysis.

Dou Jun, Executive Director of the Blockchain Special Committee of the China Industrial Communications Association and Secretary General of the RWA Global Industry Alliance in Hong Kong, shared forward-looking insights on how Chinese enterprises can promote the upgrading of the technology industry through going global and digital asset management.

From policies to platforms, from capital to technology, from intelligent decision-making to digital assets, five speeches, each pointing to going global.

Two round tables pushed the forum to a climax of ideological collision.
 

“The theme session of "Transcending Cycles, Reshaping Value - A Collaborative New Paradigm of Innovative Medicine and Capital Markets" was hosted by Liu Jianing, founding partner and director of Auburn Consulting. Yuan Quanhong, founder of Hankang Private Equity Fund, Zhu Jinqiao, founder of Yifeng Capital, Wang Junfeng, Managing Director of Junlian Capital, Zhu Yunyi, Listing Director of Tianyuan Hong Kong Law Firm, and Zhang Li, founder and CEO of Qiji Investment, participated.

In the face of capital market volatility and valuation restructuring, the discussion guests bluntly stated that capital no longer pays for stories, and cash flow and commercialization ability are the trump cards to cross cycles; Cross border listing and mergers and acquisitions are becoming important exit channels.

 Welcoming the Innovation Wave of Tumor Vaccines "is hosted by Zeng Yu, founder of Qingtu Fund. He Youwen, a tenured professor in the Department of Immunology at Duke University Medical Center, a specially appointed expert for the National Vaccine Program of the US Department of Health, and chairman of Qichen Biotechnology, Hui Aimin, founder, chairman, and CEO of Huizhengqi Pharmaceutical, Zhou Guoying, founder and chairman of Yinuo Microelectronics, and Liu Jin, co-founder and vice chairman of Wesker Biotech, participated.  

MRNA iteration, personalized vaccines, regulatory collaboration, and commercialization implementation are discussed in depth at every level. The discussion guests concluded that the breakthrough of tumor vaccines cannot be achieved without the collaboration of industry, academia, research, and medical institutions. Hong Kong's international clinical resources can serve as an accelerator.
 

The on-site communication was lively, and many viewpoints resonated.
 

After the forum, the communication continued into the night.  
 

The "Full Moon Victoria Harbour · Tonghua Night" was held at the Zhongba Guild Hall. The Victoria Harbour before Mid Autumn Festival is brightly lit. The guests had in-depth face-to-face exchanges on topics such as talent development, enterprise introduction and intellectual property protection, and the Hong Kong plan for new drug approval.
 

After the dinner, the guests boarded the cruise ship and continued their conversation in the dark of Victoria Harbour. From the guild hall to the ship, there was constant communication, and the Xiangjiang Treaty was captured in the group photo.
 

Standing at the milestone of BIOHK's fifth anniversary, with Hong Kong as the fulcrum, Tong Xieyi has achieved a leap from participant to co organizer. From innovative drugs to technology finance, from global innovation to industrial landing, the path of Tongyi's overseas expansion is becoming increasingly clear:

Chinese research and development, Hong Kong empowerment, global market. Same freehand brushwork, on the way.